Letter by Tampaki et al Regarding Article, "Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk"

Stroke. 2017 Sep;48(9):e255. doi: 10.1161/STROKEAHA.117.017989. Epub 2017 Jul 12.

Authors

Ekaterini Christina Tampaki¹, Athanasios Tampakis², Lorenz Gürke³

Affiliations

¹ Department of Propaedeutic Surgery, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
² Department of General and Visceral Surgery, Basel University Hospital, Switzerland.
³ Department of Vascular Surgery and Kidney Transplant Center, Basel University Hospital, Switzerland.

PMID: 28701575
DOI: 10.1161/STROKEAHA.117.017989

No abstract available

Publication types

Letter
Comment

MeSH terms

Benzhydryl Compounds
Blood Glucose
Cardiovascular Diseases*
Diabetes Mellitus, Type 2*
Glucosides
Humans
Hypoglycemic Agents
Risk Factors

Substances

Benzhydryl Compounds
Blood Glucose
Glucosides
Hypoglycemic Agents
empagliflozin